TERT and neuroblastoma: Since OTX015 is currently in phase II clinical trials and carfilzomib is an approved anti-tumor drug, the combination of OTX015 and carfilzomib is likely to be the first targeted therapy in the clinical trials for patients with TERT-rearrangement neuroblastoma (Chen et al., 2021).